The Russian biopharmaceutical company PSK Pharma, which is a resident of the Dubna SEZ, continues to develop the field of obstetrics and gynecology in its production. Over the past two years, the company has registered two medicines for use in these areas. This was reported in the press service of the Ministry of Investment, Industry and Science of the Moscow region.
In 2024, the company registered the drug Carbetocin PSK, used to prevent postpartum bleeding. In 2025, the drug Atoziban PSK will be introduced, which is indicated for use in pregnant women 18 years and older at risk of premature birth. Both drugs are aimed at solving problems that remain among the most acute in the field of obstetrics and gynecology.
"In the first half of 2026, PSK Pharma produced more than 5,000 packages of medicines in the field of obstetrics and gynecology. In total, since the registration of the first LP, the company has produced over 23 thousand packages. Thus, the Dubna SEZ resident makes a significant contribution to ensuring technological sovereignty in the field of drug safety of the state," said Ekaterina Zinovieva, Deputy Chairman of the Government of the Moscow Region and Minister of Investment, Industry and Science of the Moscow Region.
She also noted that PSK Pharma has the ability to scale production and increase the volume of production of these drugs in a short time.
"Registration and increasing the production of these drugs is an important step in the development of the company's gynecological field. Our task is to provide Russian doctors and patients with modern, high—quality and affordable medicines necessary to preserve women's health, the safe course of pregnancy and the period after childbirth," said Evgenia Shapiro, General Director of PSK Pharma.
Please note that this press release is based on materials provided by the company. AK&M Information Agency shall not be held liable for its contents, nor for the legal and other consequences of its publication.
